WILLEM OVERWIJK to Histocompatibility Antigens Class I
This is a "connection" page, showing publications WILLEM OVERWIJK has written about Histocompatibility Antigens Class I.
Connection Strength
0.157
-
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18; 198(4):569-80.
Score: 0.050
-
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998 Jul 20; 188(2):277-86.
Score: 0.035
-
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
Score: 0.031
-
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate. 2002 Nov 01; 53(3):183-91.
Score: 0.012
-
An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A. 2000 May 09; 97(10):5492-7.
Score: 0.010
-
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000 Jan 15; 164(2):562-5.
Score: 0.010
-
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother. 1997 Jul; 20(4):276-86.
Score: 0.008